Cardiac Hypertrophy and Related Dysfunctions in Cushing Syndrome Patients-Literature Review

J Clin Med. 2022 Nov 28;11(23):7035. doi: 10.3390/jcm11237035.

Abstract

The survival rate of adrenal Cushing syndrome patients has been greatly increased because of the availability of appropriate surgical and pharmacological treatments. Nevertheless, increased possibility of a heart attack induced by a cardiovascular event remains a major risk factor for the survival of affected patients. In experimental studies, hypercortisolemia has been found to cause cardiomyocyte hypertrophy via glucocorticoid receptor activation, including the possibility of cross talk among several hypertrophy signals related to cardiomyocytes and tissue-dependent regulation of 11β-hydroxysteroid dehydrogenase type 1. However, the factors are more complex in clinical cases, as both geometric and functional impairments leading to heart failure have been revealed, and their associations with a wide range of factors such as hypertension are crucial. In addition, knowledge regarding such alterations in autonomous cortisol secretion, which has a high risk of leading to heart attack as well as overt Cushing syndrome, is quite limited. When considering the effects of treatment, partial improvement of structural alterations is expected, while functional disorders are controversial. Therefore, whether the normalization of excess cortisol attenuates the risk related to cardiac hypertrophy has yet to be fully elucidated.

Keywords: Cushing syndrome; adrenal tumor; autonomous cortisol secretion; cardiac functional disorder; cardiac hypertrophy; cardiomyocytes; glucocorticoid excess; mortality; surgery.

Publication types

  • Review

Grants and funding

This research received no external funding.